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Over the past 15 years, insights into sterol metabolism have improved our understanding of the relationship between lipids and
common conditions such as atherosclerosis and Alzheimer’s Disease (AD). A better understanding of sterol lipid metabolism
in individuals with Down Syndrome (DS) may help elucidate how this population’s unique metabolic characteristics influence
their risks for atherosclerosis and AD. To revisit the question of whether sterol lipid parameters may be altered in DS subjects,
we performed a pilot study to assess traditional serum sterol lipids and lipoproteins, as well as markers of sterol biosynthesis,
metabolites, and plant sterols in 20 subjects with DS compared to age-matched controls. Here we report that the levels of nearly all
lipids and lipoproteins examined are similar to control subjects, suggesting that trisomy 21 does not lead to pronounced general
alterations in sterol lipid metabolism. However, the levels of serum brassicasterol were markedly reduced in DS subjects.
1. Introduction
1.1. Down Syndrome. Down Syndrome (trisomy 21) is the
most common chromosomal abnormality, occurring in
approximately 1 in 800 live births. DS is characterized by
typical dysmorphic features, congenital abnormalities, and
other medical conditions. Over the past 15 years, the life
expectancy of individuals with DS has increased significantly,
with the median age of death currently approaching 50 years
[1], an age where the incidence of many common diseases
of aging is high. Importantly, there are several differences
in the way individuals with DS appear to age compared to
the general population. Chief among these is the inevitable
appearance of Alzheimer’s Disease (AD) neuropathology
by the age of 35 years [2]. Individuals with DS have
also been reported to be relatively resistant to developing
atherosclerosis despite the presence of an unfavorable plasma
lipid profile [3]. AD and atherosclerosis are each complex,
multifactorial diseases with both genetic and environmental
contributors [4, 5]. As lipid metabolism contributes to
the pathogenesis of both disorders [4, 5], studying lipid
metabolic markers in the unique clinical situation of DS may
allow our understanding of the pathogenesis and risk factors
of these diseases to be refined for both the DS and the general
populations.
1.2. Atherosclerosis in DS. Since Murdoch described a com-
plete lack of atheroma in five institutionalized people with
DS, there has been considerable interest in DS as an
“atheroma-free” model [6]. Two subsequent post-mortem
studies also demonstrated lower atheroma burden in insti-
tutionalized individuals with DS compared to age-matched
controls [7, 8]. A recent study demonstrated reduced intima-
media thickness in the carotid arteries of community-
dwelling individuals with DS [9], which helped to address
criticisms over the institutionalized populations used in the
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previous reports. These findings are particularly striking in
light of the fact that individuals with mental retardation are
typically at increased risk for atherosclerosis [10]. Indeed,
the hypothesis that individuals with DS are protected from
the development of atherosclerosis is interesting, but an
explanation for this observation has not been elucidated to
date.
Atherosclerosis is a complex, progressive inflammatory
disorder in which dysregulated lipid metabolism plays a cen-
tral role [5]. The causal link between circulating cholesterol
levels and atherosclerosis is well established. For example,
elevated levels of low-density lipoprotein cholesterol (LDL-
C) definitively increase atherosclerosis risk [11, 12]. LDL,
which transports cholesterol from the liver to peripheral
tissues, satisfies all of Koch’s modified postulates and has a
causal role in the pathogenesis of atherosclerosis [13]. This
role is best illustrated by the success of statins and other
cholesterol lowering medications in reducing LDL-C levels,
thereby decreasing the number of cardiovascular events in
treated patients [14]. Not surprisingly, however, given the
complexity of atherosclerotic disease, lipoproteins other than
LDL may also contribute.
High-density lipoprotein (HDL) is the plasma lipopro-
tein that mediates reverse cholesterol transport, a process
that extracts excess cholesterol from peripheral tissues and
transports it to the liver to be ultimately excreted as bile
[15]. Elevated levels of HDL-C have been clearly shown to be
protective against the development of atherosclerosis even in
the context of high LDL-C levels [11, 16]. Through intense
investigations on HDL biogenesis and function, several
members of the ATP binding cassette (ABC) superfamily
have been characterized. ABCA1 and ABCG1 are genes that
encode for proteins involved in the efflux of cholesterol
from peripheral cells onto HDL [17]. ABCA1 catalyses the
initial transfer of lipids onto apolipoprotein A-I (apoA-I),
which is the rate-limiting step in the formation of nascent
HDL particles [18]. ABCG1 continues this process of adding
lipids to HDL [18]. Notably, ABCG1 localizes to the long
arm of chromosome 21 [19] and is inherited in triplicate
in most people with DS, raising interesting questions about
whether excess ABCG1 may underlie some of the differences
in lipid metabolism in this group compared to the typically
developing population. Intriguing new data from preclinical
studies show that ABCG1 also has important roles in
endothelial function, where it promotes oxysterol efflux and
protects from hypercholesterolemia-mediated endothelial
dysfunction [20]. Conversely, genetic deficiency of ABCG1
in mice promotes endothelial activation, enhances mono-
cyte adhesion and increases vascular inflammation [21].
Although these mechanisms have yet to be examined in DS
subjects, abundant ABCG1 function in the endotheliummay
help to explain their relative protection from atherosclerosis.
Studies of plant sterols have further expanded our knowl-
edge of the role of lipids in the progression of atherosclerosis.
Because a high intake of plant sterols reduces circulating
cholesterol levels [22], functional foods enriched in plant
sterols are now offered commercially as ameans to lower total
plasma cholesterol levels. Plant sterols differ from cholesterol
by the presence of a double bond at C22 and/or a methyl or
ethyl group at position C24 [22]. The major plants sterols
include campesterol (methyl C24), sitosterol, (ethyl C24),
brassicasterol (D22, methyl C24), and stigmasterol (D22,
ethyl 24). In the enterocyte, plant sterols are believed to
compete with cholesterol for incorporation into micelles,
thereby reducing cholesterol absorption [22]. Several lines
of evidence suggest that increased levels of circulating plant
sterols correspond with a decreased risk for cardiovascular
disease. Ntanios et al. have shown hamsters fed a diet
enriched in phytosterol esters have significantly fewer foam
cells, suggesting that phytosterols inhibit a key step in
the progression of atherosclerosis [23]. Fassbender et al.
have also shown an association between elevated circulating
plant sterols and a reduced tendency towards symptomatic
atherosclerosis in a Dutch cohort [24].
However, other observations complicate this issue, the
most notable of which is that sitosterolemic patients, who
have markedly increased circulating sitosterol levels, exhibit
accelerated atherogenesis [25]. Sitosterolemia is a rare auto-
somal recessive condition caused by mutations in two other
ABC transporters: ABCG5, and ABCG8 [26]. Both ABCG5
and ABCG8 are expressed exclusively in the enterocyte
and efflux plant sterols from the enterocyte back into the
intestinal lumen, thereby reducing plant sterol absorption
[27]. In sitosterolemia, lack of ABCG5/ABCG8 function
leads to significantly greater absorption of dietary cholesterol
and sitosterol and an increased incidence of cardiovascular
events independent of plasma LDL-C levels, suggesting that
sitosterol itself may be contributing to atheroma formation
[25]. A recent in vitro study also showed differential effects
of various plant sterols, both protective and deleterious, on
ABC transporter expression in foam cells [28]. There is
currently no clear consensus on the contributions of plant
sterols to the development of atherosclerosis, but recent
research suggests that numerous pathways may be involved.
It is not yet known whether plasma levels of plant sterols in
people with DS differ from the general population.
In attempts to better understand the pathogenesis of
atherosclerosis in individuals with DS, several groups have
investigated the traditional atherosclerotic risk factors of
circulating total cholesterol (TC), LDL-C, and HDL-C in the
DS population. Although these studies all vary significantly
in their sample sizes, specific outcomes, and control groups,
they nonetheless provide some useful insights into the
traditional atherosclerotic risk profiles of the DS population.
One study demonstrated a favorable lipid profile in indi-
viduals with DS, yet noted elevated levels of homocysteine,
which has been suggested to increase atherosclerosis risk
[29]. Several studies found no change in serum LDL-C or
HDL-C in individuals with DS compared to a control group
or to population norms [9, 30–32]. Many other studies
demonstrated an increased number of atherosclerotic risk
factors in individuals with DS. For example, Draheim et
al. observed elevated triglycerides and total body fat in
their DS study group [31]. These findings agree with a
much earlier study by Nishida et al. [32] and are consistent
with our current understanding of the metabolic syndrome,
which is common in DS. Other studies have also observed
a lipid profile that would suggest individuals with DS to
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be at an increased risk for atherosclerosis [29, 33]. These
widely variable results underscore the lack of consensus as
to whether lipid profiles of individuals with DS vary from
the general population and whether they confer increased
atherosclerotic risk. Notably, factors known to correlate with
atherosclerosis in the general population, such as fruit and
vegetable intake, serum LDL-C, and smoking status, all
correlate poorly with intima-media thickness in individuals
with DS [9]. This surprising result, in addition to the
conflicting data surrounding traditional atherosclerotic risk
factors, suggests that there may be some distinct mechanisms
underlying atheroma formation in DS.
1.3. Alzheimer’s Disease in DS. AD is the most common form
of dementia in the elderly and currently affects over 50%
of the general population greater than 85 years of age [4].
The vast majority (96%) of AD patients begin to experience
memory dysfunction in their 60s–80s [4]. The remaining
patients carry genetic mutations that lead to an early-onset
familial form of AD, which can manifest as early as the mid
30s [34]. All AD patients develop two neuropathological
hallmarks including amyloid plaques that consist of aggre-
gated Aβ peptides and neurofibrillary tangles that contain
hyperphosphorylated tau protein [35]. As detailed below,
the 2011 guidelines for the diagnosis of AD recognize that
changes in Aβ and tau metabolism begin to occur decades
earlier than the onset of cognitive dysfunction [36].
It is well established that DS subjects inevitably develop
amyloid and tau deposits by their mid 30s [37]. As amyloid
precursor protein (APP), the protein fromwhich Aβ peptides
are derived, is on chromosome 21, inheritance of excess APP
has been thought to underlie the accelerated onset of AD in
the DS population although this is not universally accepted
[38–41]. However, additional other mechanisms, many of
which are related to lipid metabolism, may also contribute.
First, the levels and distribution of intracellular choles-
terol can affect several aspects of APP and Aβ metabolism.
For example, the proteolytic processing of APP into Aβ
is highly influenced by intracellular cholesterol levels such
that excess cholesterol increases Aβ production whereas
cholesterol depletion minimizes it [42–45]. Once produced,
Aβ peptides are degraded, often within microglia, and
recent studies show that excess intracellular cholesterol in
microglia delays Aβ degradation whereas cholesterol efflux
from microglia promotes Aβ degradation [46].
Second, apolipoprotein E (apoE) is one of the protein
components of chylomicrons and very low-density lipopro-
teins in plasma, as well as the major apolipoprotein in the
brain [47]. The human APOE gene encodes three alleles,
apoE2, apoE3, and apoE4. In 1993, apoE genotype was
identified as a genetic risk factor for late onset AD [48, 49]
and to this day remains the most robust genetic risk factor
for late onset AD in the general population [50]. Although
exactly how apoE4 contributes to increased AD risk is not
entirely understood, apoE is known to bind Aβ and facilitates
its proteolytic degradation, with apoE4 as less efficient in Aβ
clearance than either apoE2 or apoE3 [46]. Increasing the
lipid content on apoE facilitates Aβ clearance both in vitro
and in vivo [51–55].
Third, epidemiological evidence suggests that plasma
lipid levels are associated with AD risk. Specifically, high
LDL-C and/or low HDL-C levels, particularly in midlife,
have repeatedly been associated with AD risk [56–60].
Understanding the association between circulating choles-
terol levels and AD risk has been challenging because
neither cholesterol nor apoE crosses the blood brain barrier
(BBB) [61]. However, apoA-I, the major apolipoprotein
on HDL, is capable of BBB transit and has recently been
shown to markedly affect cerebrovascular amyloid levels and
cognitive function in mouse models of AD [62, 63]. Recently,
lipidomic approaches suggest that decreased plasma sphin-
gomyelin and increased plasma ceramide mass correlate with
cognitive function in AD [64].
Finally, retrospective epidemiological studies suggest
that statins, drugs that inhibit the rate-limiting step in
cholesterol biosynthesis and are widely used to lower LDL-C
levels, reduce AD prevalence [65–67]. Although subsequent
prospective, randomized-controlled trials of statins failed to
show efficacy in the ability of statins to either prevent or treat
AD [68, 69], these trials, like many in the AD field, may have
failed because treatment was initiated past the therapeutic
window.
Identifying molecular and biochemical changes of AD
early in the disease process is necessary to allow treatment to
begin prior to neuronal loss and cognitive decline. To better
define this therapeutic window, in 2011 the National Insti-
tutes of Health (NIH) released new clinical guidelines for the
diagnosis of AD that incorporate the current understanding
of early stages in AD pathogenesis [36]. The first detectable
changes associated with AD are alterations in specific pro-
teins in the cerebrospinal fluid (CSF), specifically decreased
levels of Aβ 1–42 and increased levels of phosphorylated
tau protein. This is followed by development of amyloid
deposits in the brain, which can be visualized in a living
patient using positron emission topography (PET) with a
specific amyloid ligand known as Pittsburgh compound B
(PIB). Neuronal atrophy, which follows a distinct pattern,
later becomes detectable by magnetic resonance imaging
(MRI). Finally, cognitive problems emerge. The sequence of
AD pathology can begin up to 20 years prior to the onset
of cognitive symptoms [70]. Clearly, these new guidelines
represent an enormous advance on our ability to track the
onset and progression of AD in the general population.
Very recently, Vanmierlo et al. demonstrated that the
levels of the plant sterol brassicasterol were significantly
reduced in the CSF of cognitively impaired AD subjects
with an intact BBB [71]. Because plasma brassicasterol
levels were unchanged, reduced CSF brassicasterol levels
were hypothesized to reflect altered choroid plexus function
during the progression of AD [71]. Importantly, in this study,
CSF brassicasterol levels improved the predictive power of
the other validated CSF biomarkers, Aβ and tau. Although
their study was not designed to determine whether CSF bras-
sicasterol levels may be prognostic of AD progression, their
observations nonetheless generate interesting hypotheses
about the utility of plant sterol metabolism as a potential
biomarker in AD.
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2. Study Design
2.1. Subjects. Twenty community-dwelling subjects with DS
were assessed in this pilot study (Table 1). DS subjects were
identified from the University of Irvine California clinic or
group homes, all had clinical features of trisomy 21 and
nearly all had karyotypic analyses confirming trisomy 21.
The 22 typically developing control subjects did not have
trisomy 21 and were excluded for AD, diabetes and obesity.
Clinical Research Ethics Boards from the University of Irvine,
California and the University of British Columbia approved
this pilot study.Written informed consent was obtained from
each DS subject or caregiver and control subject.
2.2. Plasma Lipid, Lipoprotein, and CRP Analysis. TC and
HDL-C were measured from nonfasting serum by enzymatic
kits (Wako) according to the manufacturer’s protocols.
ApoA-I and apolipoprotein B100 (apoB) were measured
using an immune-nephelometric assay on the Siemens
ProSpec automated analyzer (Siemens Diagnostics, Tarry-
town, NY). The maximum interassay coefficient of variation
(CV) of the assay is 2.2% and 1.9% for apoA-I and
apoB, respectively. CRP was measured with a enzymatic
chemiluminescent immunometric assay using the Siemens
IMMULITE 2500 automated analyzer. The linear range of
the assay is 0.2–150mg/L, with a maximum interassay CV
of 8.7%.
2.3. Sterol Extraction and Analysis from Plasma. Samples
were frozen in aliquots and stored at −80◦C until analysis.
Serum concentrations of cholesterol were measured by
gas chromatography-flame ionization detection using 5α-
cholestane as internal standard. The cholesterol precur-
sors lanosterol, dihydrolanosterol, lathosterol, and desmos-
terol, the plant sterols campesterol, brassicasterol, sitos-
terol, and stigmasterol as well as the 5α-saturated com-
pounds cholestanol, campestanol and sitostanol were mea-
sured by a modified sensitive method using combined
gas chromatography-mass spectrometry (GC-MS) using
epicoprostanol as internal standard. The cholesterol oxida-
tion products, 7α-, 24S-, and 27-hydroxycholesterol, were
measured by GC-MS isotope dilution methodology using
deuterium, that is, stable isotope labeled 7α-, 24R, S-, and
27-hydroxycholesterol as internal standards [72].
Fifty μg 5α-cholestane (Serva) (50 μL from a stock
solution of 5α-cholestane in cyclohexane; 1mg/mL) and
1 μg epicoprostanol (Sigma) (10 μL from a stock solution
epicoprostanol in cyclohexane; 100 μg/mL) were added to
100 μL serum. One mL NaOH (1M) in 80% ethanol was
added and the alkaline hydrolysis was performed for 60min
at 61◦C. The sterols were subsequently extracted with 3mL
of cyclohexane twice. The organic solvents were evaporated
and the residual plasma sterols were dissolved in 160 μL
n-decane. Eighty μL of the serum n-decane samples were
transferred into microvials for gas-liquid chromatography-
mass spectrometry—selected ion monitoring (GC-MS)
of sterols, stanols and oxysterols. The sterols and stanols
were derivatized to trimethylsilyl (TMSi) ethers by adding
10 μL TMSi-reagent (pyridine : hexamethyldisilazane-
trimethylchlorosilane; 9 : 3 : 1, by volume; all reagents were
applied from Merck) and incubated for 1 h at 64◦C.
The residual 80 μL of the serum n-decane samples
were diluted with 300 μL n-decane and derivatized with
30 μL TMSi-reagent preceding analysis of cholesterol by gas
chromatography-flame ionization detection (GC-FID).
2.4. GC-FID and GC-MS. Plasma cholesterol was quantified
by GC-FID on an HP 6890 series II plus GC (Agilent
Technologies, Bo¨blingen, Germany) using 5α-cholestane as
an internal standard. An aliquot of 2 μL was injected in
a splitless mode at 280◦C by an automated sampler and
injector (HP 7683). Hydrogen was used as carrier gas with
an inlet pressure of 9.9 psi, resulting in a total gas-flow of
1.1mL/min and the temperature of the flame ionization
detector was kept at 280◦C. The sterols were separated on a
cross-linked methyl silicone DB-XLB 122-1232 fused silica
capillary column (J&W, Folsom, USA) (30m× 0.25mm i.e.,
× 0.25μm film thickness) in an Hewlett-Packard (HP 6890)
gas chromatograph. The oven temperature was initially kept
at 150◦C for 3min, and then gradually increased to a final
temperature of 290◦C. The ratios of the cholesterol areas to
the area of internal standard were calculated and multiplied
by the added amount of the internal standard (50 μg 5α-
cholestane) to reveal absolute cholesterol concentrations.
GC-MS was performed on an HP GC-MSD system
(HP 5890 series II GC) combined with a 5971 mass
selective detector (Agilent Technologies, Bo¨blingen, Ger-
many) equipped with a DB-XLB 122-1232 fused silica
capillary column (J&W, Folsom, USA) (30m× 0.25mm i.e.,
× 0.25μm film thickness) in the splitless mode using helium
(1mL/min) as the carrier gas. The temperature program
was as follows: 150◦C for 1min, followed by 20◦C/min
up to 260◦C, and 10◦C/min up to 280◦C (for 15min).
The sterols, stanols, and oxysterols were monitored as their
TMSi derivatives in the selected ion monitoring mode using
their characteristic masses [73]. Identity of all sterols was
proven by comparison with the full-scan mass spectra of
authentic compounds (range, m/z 50–500). All the above
sterols, stanols, and oxysterols were sufficiently separated on
the column from each other. Accuracy of the method was
established by recovery experiments, day to day variation
(below 3%), limit of detection and limit of quantification
below the present concentrations for each sterol.
2.5. Statistics. Data were analysed by unpaired two-tailed
Student’s t-test (GraphPad Prism v5.0), applyingWelch’s cor-
rection when variances were significantly different between
groups. A P < 0.05 was considered statistically significant.
3. Results
3.1. Study Subjects. A total of 20 community-dwelling DS
and 22 healthy, typically developing control subjects were
recruited for this pilot study. The complete cohort (Table 1)
did not differ statistically in mean age (P = 0.167) despite a
wider age range in the control compared to the DS cohort.
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Table 1: Demographics of control and DS cohorts.
Con < 45 DS < 45 Con > 45 DS > 45 Con DS
N 13 6 9 14 22 20
% male 61 83 22 64 45 70
Mean age (range) 38.92 (29–44) 42.53 (39–44) 50.78 (46–61) 47.8 (45–49) 43.77 (29–61) 46.29 (39–49)
Table 2: Serum analytes in the total control and total DS cohorts. Analytes shown in bold are significantly different between control and DS
groups by unpaired Student’s t-test. Welch’s correction was applied when variances were significantly different between groups.
Con DS P
TC (mmol/L) 4.858 (±0.743) 4.925 (±1.123) 0.834
HDL-C (mmol/L) 1.591(±0.514) 1.412 (±0.271) 0.116
ApoA-I (mg/mL) 1.4266 (±0.245) 1.324 (±0.179) 0.051
ApoB (mg/mL) 0.8028 (±0.176) 0.9015 (±0.255) 0.178
CRP (mmol/L) 1.361 ( ± 1.767) 2.847 ( ± 2.101) 0.035
Campesterol (mg/dL) 0.4953 (±0.279) 0.3424 (±0.194) 0.056
Sitosterol (mg/dL) 0.4040 ( ± 0.196) 0.2716 ( ± 0.153) 0.025
24S-OH cholesterol 64.06 (±2.540) 69.90 (±5.199) 0.296
Lathosterol (mg/dL) 0.1930 (±0.097) 0.225 (±0.130) 0.401
Campestanol (mg/dL) 3.552 (±1.385) 3.368 (±1.811) 0.729
Stigmasterol (μg/dL) 9.721 (±0.602) 11.93 (±1.115) 0.092
Sitostanol (mg/dL) 4.586 (±0.255) 4.347 (±0.436) 0.639
Lanosterol (μg/dL) 17.50 (±9.01) 21.11 (±11.17) 0.284
Dihydrolanosterol (μg/dL) 13.33 (±2.304) 14.65 (±4.385) 0.260
Desmosterol (mg/dL) 0.1401 (±0.052) 0.1295 (±0.067) 0.595
7α-OH-cholesterol (ng/mL) 72.33 (±101.0) 98.95 (±84.29) 0.382
Cholesterol (mg/dL) 185.4 (±27.51) 209.3 (±47.96) 0.071
27-OH cholesterol (ng/mL) 185.0 ( ± 54.84) 135.0 ( ± 44.69) 0.004
Cholestanol (mg/dL) 0.2825 ( ± 0.060) 0.3501 ( ± 0.088) 0.010
Brassicasterol (μg/dL) 32.07 ( ± 3.802) 11.16 ( ± 1.518) <0.0001
Because TC and HDL-C levels vary by age, we also divided
each cohort into two groups aged <45 years and >45 years
(Table 2) with no significant differences in mean age (P =
0.088 for <45 years, P = 0.131 for >45 years). However,
there are several caveats associated with our cohorts for this
pilot study. First, the DS cohort has significantly more males
than the control group, in both the pooled sample and after
dividing each cohort into two age groups. Second, control
and DS subjects were not matched for body mass index,
diabetes, diet, and exercise, all of which pose significant
potential confounds to our pilot results. Nevertheless, this
pilot study yielded some interesting observations that could
be used to design a future investigation that is sufficiently
powered and adequately matched for these variables.
3.2. Serum Lipids, Lipoproteins, Sterol Precursors, andMetabo-
lites in the Pooled Sample. No significant differences were
observed between control and DS subjects with respect to
TC, HDL-C, apoA-I, and apoB levels (Table 2). Consistent
with this, the levels of cholesterol biosynthetic intermediates
lathosterol, lanosterol, dihydrolanosterol, and desmosterol
also showed no significant differences between DS and
control groups. Cholesterol itself did not differ from controls
either when measured by an enzymatic assay or by GC-MS
(Table 2). Similarly, the levels of the rate-limiting bile acid
biosynthetic marker 7α-OH-cholesterol were unchanged
between DS and control groups (Table 2). Taken together,
these observations suggest that global cholesterol homeosta-
sis is not significantly altered by trisomy 21.
In humans, the cholesterol metabolite 24S-OH-
cholesterol is exclusively generated in the brain by the
enzyme cyp46 and plays an important role in maintaining
cholesterol homeostasis in the CNS [74, 75]. 24S-OH-
cholesterol easily crosses the BBB and its serum levels are
therefore a marker of brain cholesterol turnover. Serum
24S-OH-cholesterol levels are not significantly different
between DS and control subjects, suggesting that DS is not
associated with altered cholesterol catabolism in the CNS.
In contrast to 24S-OH-cholesterol, the ubiquitous oxysterol
27-OH-cholesterol is significantly reduced in DS subjects
compared to controls (P = 0.004).
The inflammatory marker CRP was significantly elevated
in DS subjects compared to controls (P = 0.035), as was
the sterol metabolite cholestanol (P = 0.010). Although the
levels of the plant stanols campestanol and sitostanol were
unchanged between DS and control subjects, we observed
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Figure 1: Serum brassicasterol levels are reduced in Down Syndrome (DS) subjects. Serum brassicasterol levels were quantified by GC-MS
in N = 20 DS and N = 22 healthy controls (CON). (a) Mean and standard error of brassicasterol levels in the total CON and DS sample.
(b) Mean and standard error of brassicasterol levels in the CON and DS subjects <45 and >45 years of age. (c) Mean and standard error
of brassicasterol levels in male and female CON and DS subjects. Data were analysed by Students t-test. ∗represents P < 0.05, ∗∗represents
P < 0.01, and ∗∗∗represents P < 0.001.
that serum levels of most of the plant sterols evaluated
were reduced. Most strikingly, brassicasterol levels were
remarkably lower in DS subjects (P < 0.0001) (Table 2,
Figure 1(a)). Sitosterol levels are also significantly lower in
DS subjects (P = 0.025) and campesterol levels show a
nonsignificant trend toward reduced levels in DS subjects
(P = 0.056). Stigmasterol levels were comparable in DS and
control subjects (P = 0.092).
3.3. Serum Lipids, Lipoproteins, Sterol Precursors, andMetabo-
lites by Age. When divided into two groups aged <45 and
>45 years, no significant differences were observed between
control and DS subjects with respect to TC, HDL-C, and
apoB levels (Table 3). ApoA-I levels, which were not different
in the pooled sample, were significantly reduced only in
DS subjects >45 years compared to controls (P = 0.016)
(Table 3). Whenmeasured by GC-MS, cholesterol levels were
significantly elevated only in DS subjects <45 years (P =
0.008). Similar to the pooled sample, the levels of sterol
precursors lathosterol, lanosterol, dihydrocholesterol, and
desmosterol did not differ when adjusted by age between
DS and control subjects, nor were 7α-OH-cholesterol levels
changed in either age group (Table 3). Also consistent with
the pooled sample, 24S-OH-cholesterol levels remained
unchanged when DS and controls subjects were stratified
by age (Table 3). Serum 27-OH-cholesterol levels remained
significantly lower only in DS subjects <45 years (P =
0.010, Table 3). After dividing by age, CRP levels significantly
elevated only in subjects <45 years compared to controls
(P = 0.051). Similarly, elevated levels of cholestanol were
retained only in DS subjects <45 years (P = 0.022).
Consistent with the pooled sample, levels of the plant
stanols campestanol and sitostanol remained unchanged
when DS and control subjects were grouped by age. When
stratified by age, brassicasterol levels remained greatly
reduced in DS subjects <45 years (P = 0.039) as well
as in DS subjects >45 years (P = 0.007) compared to
age-matched controls (Table 3, Figure 1(b)). Sitosterol levels
also remained significantly lower in DS subjects >45 years
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Table 3: Serum analytes in control and DS cohorts by age. Analytes shown in bold are significantly different between control and DS groups
by unpaired student’s t-test. Welch’s correction was applied when variances were significantly different between groups.
Con < 45 DS < 45 P Con > 45 DS > 45 P
TC (mmol/L) 4.859 (±0.622) 5.095 (±1.050) 0.576 4.974 (±0.793) 4.811 (±1.201) 0.727
HDL-C (mmol/L) 1.632 (±0.632) 1.357 (±0.293) 0.340 1.643 (±0.410) 1.443 (±0.268) 0.204
ApoA-I (mg/mL) 1.447 (±0.298) 1.333 (±0.179) 0.362 1.547 ( ± 0.196) 1.317 ( ± 0.188) 0.016
ApoB (mg/mL) 0.826 (±0.196) 0.918 (±0.203) 0.358 0.780 (±0.162) 0.891 (±0.293) 0.320
CRP (mmol/L) 0.800 (±1.872) 2.743 (±2.045) 0.051 1.233 (±1.806) 2.938 (±2.286) 0.107
Campesterol (mg/dL) 0.5406 (±0.333) 0.4378 (±0.283) 0.547 0.4894 ( ± 0.219) 0.3015 ( ± 0.114) 0.014
Sitosterol (mg/dL) 0.437 (±0.238) 0.352 (±0.225) 0.506 0.422 ( ± 0.213) 0.2369 ( ± 0.102) 0.010
24S-OH cholesterol 63.67 (±3.122) 66.50 (±15.20) 0.721 60.78 (±3.172) 71.36 (±7.038) 0.187
Lathosterol (mg/dL) 0.2039 (±0.115) 0.2703 (±0.092) 0.259 0.1951 (±0.085) 0.2054 (±0.141) 0.847
Campestanol (mg/dL) 3.639 (±1.704) 4.138 (±2.789) 0.672 3.659 (±0.990) 3.038 (±1.187) 0.207
Stigmasterol (mg/dL) 10.09 (±1.092) 13.99 (±3.103) 0.280 10.33 (±1.996) 11.04 (±3.360) 0.572
Sitostanol (mg/dL) 4.709 (±1.394) 5.338 (±3.018) 0.591 4.790 (±1.106) 3.921 (±1.183) 0.084
Lanosterol (mg/dL) 20.11 (±11.26) 21.80 (±10.60) 0.776 18.60 (±10.15) 20.81 (±11.79) 0.648
Dihydrolanosterol (mg/dL) 13.66 (±2.625) 14.25 (±4.562) 0.739 13.60 (±3.067) 14.81 (±4.473) 0.487
Desmosterol (mg/dL) 0.1522 (±0.063) 0.1413 (±0.058) 0.741 0.1352 (±0.047) 0.1244 (±0.073) 0.696
7α-OH-cholesterol (ng/mL) 86.89 (±47.13) 81.67 (±1.60) 0.919 57.78 (±34.59) 106.4 (±97.33) 0.167
Cholesterol (mg/dL) 178.8 ( ± 22.16) 222.2 ( ± 32.25) 0.008 192.3 (±30.57) 203.8 (±53.01) 0.564
27-OH cholesterol (ng/mL) 219.1 ( ± 57.88) 135.0 ( ± 44.99) 0.010 164.8 (±46.98) 135.0 (±46.27) 0.149
Cholestanol (mg/dL) 0.2743 ( ± 0.070) 0.3727 ( ± 0.085) 0.022 0.2976 (±0.059) 0.3404 (±0.091) 0.274
Brassicasterol (mg/dL) 35.40 ( ± 17.83) 14.12 ( ± 10.90) 0.039 33.07 ( ± 19.02) 9.886 ( ± 3.99) 0.007
(P = 0.010) and campesterol levels were also significantly
reduced in this age group of DS subjects (P = 0.014) com-
pared to controls. Similar to the pooled groups, stigmasterol
levels were comparable in DS and control subjects at each age
examined (<45 y: P = 0.280, >45 y: P = 0.572).
3.4. Serum Brassicasterol Levels Are Significantly Reduced in
Both Male and Female DS Subjects. Of all of the analytes
examined, brassicasterol appears to have the most robust
association with DS, being dramatically lower in both the
pooled sample and in each age group. However, because
a major caveat of our study is that the DS cohort had
significantly more male subjects, particularly for the group
>45 years, we also analysed serum brassicasterol levels
independently in male and female DS subjects compared to
controls. We observed significantly lower brassicasterol levels
in male (P = 0.009) and female (P = 0.002) DS subjects
compared to controls (Figure 1(c)).
4. Discussion
Although atherosclerosis is a multifactorial disease with
environmental factors integral to its progression, several lines
of evidence suggest that environmental differences alone
cannot explain the apparent resistance to atherosclerosis in
the DS population. The pathology reports that first described
DS as an atheroma-free population compared DS subjects
to other institutionalized controls [6]. Presumably, factors
such as exercise, diet, and other environmental variables were
comparable between these two non-community-dwelling
groups, suggesting that their different atheroma burden may
be independent of environmental factors [6–8]. Through
dietary surveys given to a group of individuals with DS
residing in the community, Braunschweig et al. concluded
that people with DS consumed a comparable diet to that of
the general population [30].
Being a pilot study, our results have several associated
caveats. Our sample is small in size, poorly matched for
gender, and lacks nutritional information. Because our goal
was to compare traditional sterol lipid profiles between
people with DS and healthy typically developing controls, we
did not specifically recruit a group of controls with normal
intellectual ability who were matched for body mass index
and diet with DS subjects. This will be an essential additional
control group for future studies. The lipids to be analysed
in the future should be expanded to include cholesteryl
esters, sphingomyelin, gangliosides, and lipids involved in
signaling, as these factors can contribute to an overall change
in lipidomic profiles in both AD and atherosclerosis and may
offer additional insights into how such lipids may affect AD
or cardiovascular risk [76, 77].
Despite these caveats, our pilot investigation suggests that
the traditional atherosclerotic risk factors in people with DS
generally do not differ from typically developing controls and
are in accordance with several previous studies [9, 30–32].
Specifically, TC, HDL-C, and apoB were comparable in all of
our subsets. Although differences in apoA-I and cholesterol
measured by GC-MS did reach statistical significance in
some subsets, these changes were not retained across age
groups or genders. These observations, in addition to
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the finding that markers of cholesterol biosynthesis and
metabolism are also not significantly altered in DS subjects,
suggest that the overall sterol metabolic profile in DS is
similar to the general population. Our study revealed that
cholestanol levels were increased in younger subjects with
DS, whereas 27-OH levels were reduced, but the significance
of these observations is not immediately obvious. Our study
is the first to test for alterations in circulating 24S-OH-
cholesterol levels in subjects with DS compared to controls.
In humans, 24S-OH-cholesterol is exclusively generated in
CNS neurons and easily crosses the BBB, where its levels
in the circulation reflect sterol turnover in the CNS [75].
Again, no changes were observed, suggesting that overall
sterol metabolism in the DS brain is similar to that in the
general population.
The major conclusion of our pilot study is that serum
brassicasterol levels are significantly reduced in people with
DS. The mechanism responsible for this change is unclear, as
there is no obvious physiological explanation for this finding.
However, the reduction is robust and persists across genders
and age groups. Because plant sterols are entirely derived
from the diet, the lack of dietary information in the DS and
controls subjects studied here is an obvious caveat to our
study. However, we believe that dietary differences alone are
unlikely to entirely account for the reduced brassicasterol
levels in DS subjects, as community-dwelling individuals
with DS have previously been shown to consume similar
diets as control subjects [30] and that other diet-derived
plant sterols studied here were not significantly altered
between DS and control subjects. Our findings raise inter-
esting questions about the mechanisms underlying reduced
brassicaterol levels and the effects of low brassicaterol levels
on atherosclerosis risk. Plant sterols have atheroprotective
properties attributed to their ability to reduce cholesterol
absorption, yet TC, HDL-C, apoB and most plant sterol
levels were comparable between DS and control subjects. If
anything, low brassicaterol levels would argue in favor of
increased risk and raise questions about whether different
plant sterols have distinct effects.
Although much remains to be explored in this area,
it is likely that genetic factors in DS may have a larger
effect compared to environmental factors in modulating
atherosclerosis risk. Fetal tissues have been used to determine
whether trisomy 21 leads to genetically determined differ-
ences in lipid metabolism between DS and control subjects,
as the blood-placental barrier maintains separation between
the fetal and maternal circulation [78]. Therefore, nearly
all cholesterol present in fetal blood is synthesized by the
fetus itself. One study showed that serum TC levels are
elevated in fetuses with DS, and a follow-up study by the
same authors demonstrated elevated cholesterol levels in DS
fetal liver samples [79, 80]. Although more work needs to
be done to better define the metabolic differences in DS,
this area has considerable potential to establish genetically-
defined baseline lipid and lipoprotein levels in people with
DS. One particularly promising area of research may be
to investigate the role of ABCG1 on endothelial function
in DS, given that studies in preclinical models suggest
that excess ABCG1 may promote endothelial resistance to
triggers of atherosclerosis [20, 21]. Although there is no
firm consensus, some preclinical studies support a role for
ABCG1 in atherosclerosis in specific animal models [81–
84]. However, none of these studies specifically investigated
endothelial function in their model systems. It is conceivable
that the possible protection from atherosclerosis in the DS
population may not be strongly associated with plasma lipid
levels but rather may be due to better endothelial function.
An important question raised by our pilot study is
whether brassicaterol levels in the CSF or brain tissue of
DS subjects is altered compared to controls. Decreased
CNS brassicaterol levels in DS would support the previous
association with validated CSF Aβ and tau biomarkers
for AD in the general population [71]. An important
consideration for further investigation in this area is to
include young DS subjects, as our subject group is of
a mean age that would already invariably exhibit AD
neuropathology. It is unclear, in both the general and DS
populations, if changes in brassicasterol levels precede the
development of AD neuropathology or dementia. The new
AD diagnostic guidelines offer an unprecedented ability to
study how the trajectory of AD pathogenesis may differ in
DS subjects. Our preliminary results suggest that inclusion
of CNS brassicasterol measurements may also add to the
possible understanding of AD pathogenesis in the unique DS
population.
5. Conclusions
In people with DS, standard serum markers of sterol lipid
metabolism are generally unchanged from age-matched
controls and offer little insight into why DS subjects appear
to have reduced prevalence of atherosclerotic disease. Further
investigation into ABCG1 function, which is inherited in
triplicate in trisomy 21 and plays roles in HDL metabolism
and endothelial function, may prove more informative.
Among the many analytes examined in our study, serum
levels of the plant sterol brassicasterol levels were remarkably
reduced in DS subjects relative to healthy controls across age
and gender. As CSF brassicasterol levels have been reported
to be reduced in AD patients and to improve the predictive
power of CSF Aβ and tau levels as AD biomarkers, it will be
of interest to determine whether serum and CSF brassicaterol
levels are reduced in DS subjects throughout their lifespan
or could be used as a prognostic biomarker of incipient AD
neuropathology in DS subjects.
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